Clinical trial
Clinical Study of CDP870/Certolizumab Pegol in Patients With Active Crohn's…
NCT00291668 · UCB Pharma, Industry · Completed
Key facts
| NCT number | NCT00291668 |
|---|---|
| Title | Clinical Study of CDP870/Certolizumab Pegol in Patients With Active Crohn's Disease |
| Official title | A Phase II, Multi-center, Double-blind, Placebo-controlled, Parallel-group, Dose-response Study to Assess the Safety and Efficacy of CDP870/Certolizumab Pegol, Dosed Subcutaneously in Patients With Active Crohn's Disease |
| Lead sponsor | UCB Pharma, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Crohn's Disease |
| Intervention type | Biological, Other |
| Interventions | Certolizumab Pegol, Placebo |
| Enrollment | 94 |
| Start date | Mar 2, 2006 |
| Primary completion | Nov 8, 2007 |
| Completion | Nov 8, 2007 |
| First posted | Feb 14, 2006 |
| Last update posted | Aug 3, 2020 |
| Countries | Japan |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: